NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression

International Journal of Cancer

Volumn 132, Issue 1, 2013, Pages 9-18

  Okayama, Hirokazu ^a,b   Saito, Motonobu ^a,b   Oue, Naohide ^a   Weiss, Jonathan M ^c   Stauffer, Jimmy ^c   Takenoshita, Seiichi ^b   Wiltrout, Robert H ^c   Hussain, S Perwez ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

inflammation; KRAS; lung cancer; miR 21; NOS2

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; K RAS PROTEIN; MICRORNA 21; RAS PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE LOSS; IN SITU HYBRIDIZATION; INTRACELLULAR SIGNALING; LUNG ADENOMA; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOGENESIS; LUNG CARCINOMA; MOUSE; NONHUMAN; NOS2 GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME;

ANIMALS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; FORKHEAD TRANSCRIPTION FACTORS; INFLAMMATION; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MUTATION; NITRIC OXIDE SYNTHASE TYPE II; PROTO-ONCOGENE PROTEINS P21(RAS); PULMONARY ALVEOLI; T-LYMPHOCYTES, REGULATORY;

EID: 84868205548     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27644     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Herbst RS, Heymach JV, Lippman SM,. Lung cancer. N Engl J Med 2008; 359: 1367-80.
3. Downward J,. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
4. Sparmann A, Bar-Sagi D,. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-58.
5. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011; 103: 1112-22.
6. Ancrile B, Lim KH, Counter CM,. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007; 21: 1714-19.
7. Ji H, Houghton AM, Mariani TJ, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006; 25: 2105-12.
8. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005; 65: 3226-35.
9. Moghaddam SJ, Li H, Cho SN, et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 2009; 40: 443-53.
10. Sunaga N, Imai H, Shimizu K, et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 2012; 130: 1733-44.
11. Krol J, Loedige I, Filipowicz W,. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
12. Schetter AJ, Heegaard NH, Harris CC,. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49.
13. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
14. Fujita K, Mondal AM, Horikawa I, et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009; 11: 1135-42.
15. Seike M, Goto A, Okano T, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009; 106: 12085-90.
16. Frezzetti D, De Menna M, Zoppoli P, et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 2011; 30: 275-86.
17. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18: 282-93.
18. Yang CH, Yue J, Fan M, et al. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010; 70: 8108-16.
19. Mathe E, Nguyen GH, Funamizu N, et al. Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide. Int J Cancer, 2012; 131: 760-5.
20. Kanwar JR, Kanwar RK, Burrow H, et al. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem 2009; 16: 2373-94.
21. Weiss JM, Ridnour LA, Back T, et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 2010; 207: 2455-67.
22. Thomas DD, Espey MG, Ridnour LA, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004; 101: 8894-9.
23. Kobayashi Y,. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol 2010; 88: 1157-62.
24. Ambs S, Merriam WG, Ogunfusika MO, et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4: 1371-6.
25. Hussain SP, Trivers GE, Hofseth LJ, et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 2004; 64: 6849-53.
26. Hussain SP, He P, Subleski J, et al. Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res 2008; 68: 7130-6.
27. Ambs S, Glynn SA,. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. Cell Cycle 2011; 10: 619-24.
28. Prueitt RL, Boersma BJ, Howe TM, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007; 120: 796-805.
29. Pervin S, Singh R, Hernandez E, et al. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res 2007; 67: 289-99.
30. Kisley LR, Barrett BS, Bauer AK, et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 2002; 62: 6850-6.
31. Nam KT, Oh SY, Ahn B, et al. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut 2004; 53: 1250-5.
32. Ellies LG, Fishman M, Hardison J, et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003; 106: 1-7.
33. Fukumura D, Kashiwagi S, Jain RK,. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-34.
34. Hirst D, Robson T,. Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy. Curr Pharm Des 2010; 16: 411-20.
35. Liu CY, Wang CH, Chen TC, et al. Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer 1998; 78: 534-41.
36. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 4739-44.
37. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-8.
38. Saito M, Kumamoto K, Robles AI, et al. Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS One 2010; 5: e15541.
39. Nikitin AY, Alcaraz A, Anver MR, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004; 64: 2307-16.
40. Murray AB, Luz A,. Acidophilic macrophage pneumonia in laboratory mice. Vet Pathol 1990; 27: 274-81.
41. Hoenerhoff MJ, Starost MF, Ward JM,. Eosinophilic crystalline pneumonia as a major cause of death in 129S4/SvJae mice. Vet Pathol 2006; 43: 682-8.
42. Weiss JM, Back TC, Scarzello AJ, et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci USA 2009; 106: 19455-60.
43. Voortman J, Goto A, Mendiboure J, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010; 70: 8288-98.
44. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-44.
45. Yang G, Rosen DG, Zhang Z, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 16472-7.
46. Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer. Adv Cancer Res 2010; 107: 57-117.
47. Brahmachari S, Pahan K,. Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide. J Immunol 2010; 184: 1799-809.
48. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011; 17: 1875-82.
49. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.
50. Talotta F, Cimmino A, Matarazzo MR, et al. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009; 28: 73-84.